This study proposes EA‐ST36 as a promising therapeutic strategy for counteracting HFD‐induced AD pathology by activating TFEB/TFE3‐driven autophagic pathways, thereby enhancing the clearance of toxic protein aggregates and inflammasome components. Here, TFEB is linked to Alzheimer disease.